Supraflex Stent Clinically at Par With Global Standards

Transcatheter Cardiovascular Therapeutics 2018 (TCT) conference, California

Supraflex, a cardiac drug eluting stent designed and manufactured in India has been confirmed to be at par with Abbott’s Xience through an investigators-driven study called ‘TALENT’ – Thin strut sirolimus-eluting stent in all-comers population vs everolimus eluting stent. Supraflex is made by Sahajanand Medical Technologies (SMT), Indian medical devices manufacturer specializing in the provision of life-changing vascular solutions.

The findings of the TALENT trial were presented at the ‘late breaking trial session’ at Transcatheter Cardiovascular Therapeutics 2018 (TCT), the largest global conference of cardiologist currently underway in San Diego. This study was conducted in 7 countries – United Kingdom, Netherlands, Poland, Spain, Italy, Hungary and Bulgaria – across 23 renowned centres with a sample size of 1435 patients. Xience is regarded as global standard in safety and efficacy for drug eluting stents. Renowned cardiologist, Dr. Patrick Serruys was the chair for the TALENT trial. Prof. R. de Winter, MD, Academisch Medisch Centrum, Amsterdam, The Netherlands; and A. Zaman, MD, Cardiac Catheter Laboratories, Royal Freeman, Newcastle, UK, were the Principal Investigators for the TALENT trial.

Presenting the findings of TALENT trial, Dr. Patrick Serruys, said, “Safety and efficacy of Supraflex SES with ultra thin struts and biodegradable polymer were compared with …

To read more subscribe
Show More

Related Articles

Leave a Reply